Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy

David M. Goldenberg, Robert M. Sharkey, Giovanni Paganelli, Jacques Barbet, Jean François Chatal

Research output: Contribution to journalArticlepeer-review

Abstract

This article reviews the methods of pretargeting, which involve separating the targeting antibody from the subsequent delivery of an imaging or therapeutic agent that binds to the tumor-localized antibody. This provides enhanced tumor:background ratios and the delivery of a higher therapeutic dose than when antibodies are directly conjugated with radionuclides, as currently practiced in cancer radioimmunotherapy. We describe initial promising clinical results using streptavidin-antibody constructs with biotin-radionuclide conjugates in the treatment of patients with malignant gliomas, and of bispecific antibodies with hapten-radionuclides in the therapy of tumors expressing carcinoembryonic antigen, such as medullary thyroid and small-cell lung cancers.

Original languageEnglish
Pages (from-to)823-834
Number of pages12
JournalJournal of Clinical Oncology
Volume24
Issue number5
DOIs
Publication statusPublished - Feb 10 2006

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy'. Together they form a unique fingerprint.

Cite this